February 22, 2021
Continued here:
Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)
Related Post
- Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences - March 6th, 2021
- Novan to Present at the H.C. Wainwright Global Life Sciences Conference - March 6th, 2021
- MediPharm Labs Closes Previously Announced Bought Deal Equity Financing - March 6th, 2021
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced... - March 6th, 2021
- Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference - March 6th, 2021
- Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to... - March 6th, 2021
- Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings - March 6th, 2021
- Number of voting rights as of March 5, 2021 - March 6th, 2021
- Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19 - March 6th, 2021
- Bavarian Nordic to Host Full Year 2020 Results Conference Call - March 6th, 2021
- 22nd Century Group to Participate in Investor Conferences in March 2021 - March 6th, 2021
- Lowell Farms Inc. Emerges From Acquisition With an Eye Toward Dominance in California’s Cannabis Industry and Beyond - March 6th, 2021
- Vor Biopharma to Present at the Barclays Global Healthcare Conference - March 6th, 2021
- Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference - March 6th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021 - March 6th, 2021
- Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021 - March 6th, 2021
- AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement - March 6th, 2021
- DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference - March 6th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6th, 2021
- Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection - March 6th, 2021
- Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - March 4th, 2021
- Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021 - March 4th, 2021
- Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - March 4th, 2021
- Retrotope to Present at H.C. Wainwright Global Life Sciences Conference - March 4th, 2021
- Radius Health, Inc. Announces $175 Million Financing Transaction - March 4th, 2021
- Salarius Announces Proposed Public Offering of Common Stock - March 4th, 2021
- electroCore to Participate at Two Upcoming Investor Conferences - March 4th, 2021
- PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences - March 4th, 2021
- Transparency notification received from The Capital Group - March 4th, 2021
- InMed to Present at Virtual Conferences in March 2021 - March 4th, 2021
- DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results - March 4th, 2021
- Tower One Secures MLA With “WOM”- Novator Partners LLP - March 4th, 2021
- Osmotica to Present at Barclays Global Healthcare Conference 2021 - March 4th, 2021
- Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial - March 4th, 2021
- FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma - March 4th, 2021
- argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update - March 4th, 2021
- Addex to Present at the H.C. Wainwright Global Life Sciences Conference - March 4th, 2021
- Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector - March 4th, 2021
- Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 - March 4th, 2021
- GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES - March 4th, 2021
- Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics - March 2nd, 2021
- Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results - March 2nd, 2021
- Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress... - March 2nd, 2021
- Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results - March 2nd, 2021
- Motus GI to Participate in Two Upcoming Investor Conferences in March 2021 - March 2nd, 2021
- VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference - March 2nd, 2021
- FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results - March 2nd, 2021
- Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021 - March 2nd, 2021
- Bioventus to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 25, 2021 - March 2nd, 2021
- Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15 - March 2nd, 2021
- Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights - March 2nd, 2021
- Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates - March 2nd, 2021
- Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021 - March 2nd, 2021
- Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors - March 2nd, 2021
- Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - March 2nd, 2021
- LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia... - March 2nd, 2021
- Nephros Reports 2020 Fourth Quarter and Full Year Financial Results - March 2nd, 2021
- Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021 - March 2nd, 2021
- Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - March 2nd, 2021
- MediPharm Labs Announces $20 million Bought Deal Equity Financing - March 2nd, 2021
- Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE - February 28th, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 28th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 28th, 2021
- Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients - February 28th, 2021
- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization... - February 28th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 28th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 28th, 2021
- UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use... - February 28th, 2021
- Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 28th, 2021
- Supernus to Present at Cowen Healthcare Conference - February 28th, 2021
- Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients - February 28th, 2021
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 28th, 2021
- Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - February 28th, 2021
- Orphazyme announces participation in upcoming virtual investor conferences - February 28th, 2021
- Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany - February 28th, 2021
- Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights - February 28th, 2021
- Zomedica Corp. Announces Year End 2020 Financial Results - February 28th, 2021
- NextCure to Host Virtual R&D Update Event on March 4, 2021 - February 28th, 2021
- GENFIT: Revenues and Cash Position as of December 31, 2020 - February 28th, 2021
- Annual financial report 2020 - February 28th, 2021
